非酒精性脂肪性肝炎药物临床试验合并症的管理

摘要/Abstract

摘要： 非酒精性脂肪性肝炎(NASH)发病机制尚不清楚,目前正在进行一些NASH相关代谢靶点的药物临床试验,本文综述了目前治疗NASH药物临床试验的现状。另外,NASH的药物临床试验面临许多挑战,如NASH患者存在许多合并症,这些合并症及治疗对药物临床试验的结果和分析都会产生影响,本文对纳入药物临床试验以及试验过程中NASH患者合并症的管理进行综述,旨在为NASH患者相关合并症的管理提供建议。

刘是奕, 王点, 刘静, 唐栋, 陈公英. 非酒精性脂肪性肝炎药物临床试验合并症的管理[J]. 肝脏, 2023, 28(12): 1405-1407.

参考文献

[1] Cusi K,Isaacs S,Barb D,et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)[J]. Endocr Pract,2022,28(5):528-562.
[2] Raza S, Rajak S, Upadhyay A,et al. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed),2021,26(2):206-237.
[3] Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease[J]. J Intern Med. 2022,292(2):190-204.
[4] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
[5] Pais R, Cariou B, Noureddin M, et al.Liver Forum NAFLD-Associated Comorbidities Working Group. A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials[J]. J Hepatol,2023,79(3):829-841
[6] Wagner N, Wagner KD. The Role of PPARs in Disease. Cells,2020,9(11):2367.
[7] Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial[J]. Hepatology,2021,74(4):1809-1824.
[8] Francque SM, Bedossa P, Ratziu V, et al..A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med[J],2021,385(17):1547-1558.
[9] Sanyal AJ, Chalasani N, Kowdley KV, et al .Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med,2010,362(18):1675-1685.
[10] Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis[J]. N Engl J Med,2021 ,384(12):1113-1124.
[11] Younossi ZM, Ratziu V, Loomba R, et al; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet,2019,394(10215):2184-2196.
[12] Ahsan F, Oliveri F, Goud HK, et al . Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis[J]. Cureus, 2020,12(9):e10446.
[13] Hegele RA, Ginsberg HN, Chapman MJ, et al; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management[J]. Lancet Diabetes Endocrinol,2014 ,2(8):655-666.
[14] Cazzo E, Jimenez LS, Gestic MA, et al . Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features[J]. Obes Surg,2018,28(1):187-194.
[15] American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019[J]. Diabetes Care,2019,42(Suppl 1):S61-S70.
[16] Cui J, Philo L, Nguyen P, et al . Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol,2016,65(2):369-376.
[17] Davies MJ, Aroda VR, Collins BS, et al . Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetologia, 2022,65(12):1925-1966.
[18] Zhang X, Wong GL, Yip TC, et al . Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease[J]. Hepatology,2022 ,76(2):469-482.
[19] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis[J]. Gastroenterology,2015,149(2):367-78.e5; quiz e14-5.
[20] Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial[J]. Lancet,2023,401(10390):1786-1797.
[21] Moolla A, Motohashi K, Marjot T, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health[J]. Frontline Gastroenterol, 2019,10(4):337-346.
[22] Zou ZY, Ren TY, Fan JG. Multidisciplinary participation: The key to a cure for non-alcoholic fatty liver disease[J]. J Dig Dis,2021,22(12):680-682.
[23] 李国超,于嫚,李晓菲,等.非酒精性脂肪性肝炎治疗靶点和靶向药物研发进展[J].河北工业科技,2023,40(03):225-234.
[24] Raza S, Rajak S, Upadhyay A, et al . Current treatment paradigms and emerging therapies for NAFLD/NASH[J]. Front Biosci (Landmark Ed),2021,26(2):206-237.